- Home
- CIVB vs XFOR Comparison
CIVB vs XFOR Comparison
Compare CIVB & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CIVB | XFOR |
|---|---|---|
| Founded | 1884 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 466.8M | 407.5M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | CIVB | XFOR |
|---|---|---|
| Price | $22.63 | $4.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $26.00 | $25.20 |
| AVG Volume (30 Days) | 68.3K | ★ 489.7K |
| Earning Date | 04-22-2026 | 03-17-2026 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | ★ 31.34 | N/A |
| EPS | ★ 2.64 | N/A |
| Revenue | ★ $19,023,000.00 | N/A |
| Revenue This Year | $15.33 | N/A |
| Revenue Next Year | $6.44 | $80.31 |
| P/E Ratio | $8.55 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.47 | $0.17 |
| 52 Week High | $25.59 | $6.63 |
Technical Indicators
Market Signals| Indicator | CIVB | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 55.43 |
| Support Level | $21.45 | $3.01 |
| Resistance Level | $23.20 | $4.34 |
| Average True Range (ATR) | 0.63 | 0.36 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 70.95 | 69.39 |
Price Performance
Historical ComparisonAbout CIVB Civista Bancshares Inc.
Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.